Trial Profile
To evaluate the safety of Idarucizumab and to compare the clinical outcomes of patients treated with four-factor prothrombin complex concentrate for warfarin reversal
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Idarucizumab (Primary)
- Indications Blood coagulation disorders
- Focus Adverse reactions; Therapeutic Use
- 28 Nov 2017 New trial record